SEC 13F Intelligence

Managers / Q3 2024 · view latest →

BML Capital Management, LLC

CIK 0001616824 · 65 E CEDAR - SUITE 2, ZIONSVILLE, IN, 46077 · 317-344-2447

Reported Value
$170M
Q3 2024
Positions
29
Filings on Record
16
2019–present window
Filed
Nov 5, 2024
original filing

Summary

Bml Capital Management, LLC reported $170M in U.S.-listed holdings across 29 positions for Q3 2024.

Its largest position, Ishares Tr, represents 16.0% of the portfolio.

Compared with Q2 2024, the fund opened 5 new positions and exited 4.

Portfolio Metrics

Turnover
+9.5%
vs prior filed quarter
Top-10 Concentration
+84.8%
share of reported value
Largest Position
+16.0%
Ishares Tr
New / Exited
5 / 4
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’22: $105MQ4 ’22Q1 ’23: $116MQ2 ’23: $111MQ2 ’23Q3 ’23: $109MQ4 ’23: $132MQ4 ’23Q1 ’24: $152MQ2 ’24: $140MQ2 ’24Q3 ’24: $170MQ4 ’24: $161MQ4 ’24Q1 ’25: $124MQ2 ’25: $132MQ2 ’25Q3 ’25: $109MQ4 ’25: $116MQ4 ’25Q1 ’26: $156Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 65.2%ETP: 25.5%Other: 6.8%ADR: 2.5%
  • Common Stock · 65.2% · $111M
  • ETP · 25.5% · $43M
  • Other · 6.8% · $12M
  • ADR · 2.5% · $4M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
ANTXAN2 THERAPEUTICS INCNEW+5.75M5.75M+$6M$6M
WHWKAADI BIOSCIENCE INCNEW+2.00M2.00M+$4M$4M
PIERIS PHARMACEUTICALS INCNEW+42.1K42.1K+$698,515$698,515
FBRXFORTE BIOSCIENCES INCNEW+70.5K70.5K+$393,916$393,916
HILLEVAX INCNEW+19.8K19.8K+$34,778$34,778
698ACHILLES THERAPEUTICS PLCADDED+3.47M4.10M+$4M$4M
TLISTALIS BIOMEDICAL CORPADDED+206.0K248.7K+$89,868$460,099
WINGWINGSTOP INCSOLD OUT−7140−$4M$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2024

29 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1ISHARES TR0-3 MNTH TREASRY16.00%$27M270.0K
2TILINSTIL BIO INChistory →COM NEW13.27%$23M335.0K
3AVIRATEA PHARMACEUTICALS INChistory →COM13.11%$22M6.65M
4ACRSACLARIS THERAPEUTICS INChistory →COM9.64%$16M14.25M
5SPDR SER TRBLOOMBERG 1-3 MO9.45%$16M175.0K
6AVU0ADVERUM BIOTECHNOLOGIES INChistory →COM NEW9.37%$16M2.27M
7TECXTECTONIC THERAPEUTIC INChistory →COM3.78%$6M211.8K
8ANTXAN2 THERAPEUTICS INChistory →COM3.62%$6M5.75M
9RENEO PHARMACEUTICALS INCCOM3.46%$6M3.46M
10ORMPORAMED PHARMACEUTICALS INChistory →COM NEW3.14%$5M2.19M
11698ACHILLES THERAPEUTICS PLChistory →SPONSORED ADS2.46%$4M4.10M
12WHWKAADI BIOSCIENCE INChistory →COM2.42%$4M2.00M
13CONNECT BIOPHARMA HLDGS LTDADS1.77%$3M2.09M
14PMVPPMV PHARMACEUTICALS INChistory →COM1.48%$3M1.69M
15ASTCASTROTECH CORPhistory →COM1.04%$2M220.4K
16MISTMILESTONE PHARMACEUTICALS INhistory →COM1.02%$2M1.14M
17LENZLENZ THERAPEUTICS INCCOM0.84%$1M60.0K
18IKENA ONCOLOGY INCCOM0.74%$1M723.3K
19VNDAVANDA PHARMACEUTICALS INCCOM0.63%$1M228.5K
20LSTALISATA THERAPEUTICS INCCOM0.50%$854,007284.7K
21PIERIS PHARMACEUTICALS INCCOM NEW0.41%$698,51542.1K
22CALCCALCIMEDICA INCCOM NEW0.40%$681,719153.9K
23ALLOVIR INCCOM0.29%$487,595603.1K
24TLISTALIS BIOMEDICAL CORPCOM NEW0.27%$460,099248.7K
25VTGNVISTAGEN THERAPEUTICS INCCOM0.27%$451,500150.0K
26FBRXFORTE BIOSCIENCES INCCOM NEW0.23%$393,91670.5K
27NXTCEURNEXTCURE INCCOM0.22%$378,757276.5K
28VERRICA PHARMACEUTICALS INCCOM0.15%$261,000180.0K
29HILLEVAX INCCOM0.02%$34,77819.8K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$156M16May 6, 202613F-HRchanges · EDGAR ↗
Q4 2025$116M16Feb 3, 202613F-HRchanges · EDGAR ↗
Q3 2025$109M20Nov 10, 202513F-HRchanges · EDGAR ↗
Q2 2025$132M24Aug 11, 202513F-HRchanges · EDGAR ↗
Q1 2025$124M27May 7, 202513F-HRchanges · EDGAR ↗
Q4 2024$161M25Feb 7, 202513F-HRchanges · EDGAR ↗
Q3 2024$170M29Nov 5, 202413F-HRchanges · EDGAR ↗
Q2 2024$140M28Aug 7, 202413F-HRchanges · EDGAR ↗
Q1 2024$152M32Apr 24, 2024RESTATEMENTchanges · EDGAR ↗
Q4 2023$132M35Feb 2, 2024RESTATEMENTchanges · EDGAR ↗
Q3 2023$109M26Oct 23, 202313F-HRchanges · EDGAR ↗
Q2 2023$111M31Jul 24, 202313F-HRchanges · EDGAR ↗
Q1 2023$116M31Apr 14, 202313F-HRchanges · EDGAR ↗
Q4 2022$105M25Feb 13, 202313F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.